IMMUNOHISTOCHEMICAL VALIDATION OF INSULIN-LIKE GROWTH FACTOR II mRNA-BINDING PROTEIN 3 (IMP3) AS A DIAGNOSTIC MARKER IN SALIVARY GLAND TUMORS

Document Type : Original Article

Authors

1 Instructor in Oral Pathology Department, Faculty of Dentistry, Alexandria University.

2 Professor in Oral Pathology Department, Faculty of Dentistry, Alexandria University.

3 Professor in Cranio-Maxillofacial and Plastic Surgery Department, Faculty of Dentistry, Alexandria University.

4 Lecturer in Oral Pathology Department, Faculty of Dentistry, Alexandria University.

Abstract

Introduction: Salivary gland tumors (SGTs) are infrequent tumours accounting for 2-6.5% of all head and neck tumors. They show various clinical behaviours and different histological patterns resulting in a diagnostic dilemma. Insulin like growth factor II RNA binding protein 3 (IMP3) is an oncofetal protein that plays an important role in tumor invasion and metastases. Several studies proved the prognostic role of IMP3 in different human cancers. However, its role in SGTs still needs to be confirmed.
Objectives: To evaluate IMP3 immunoexpression in benign and malignant SGTs.
Material and Methods: IMP3 expression was measured in 44 SGT cases (20 benign and 24 malignant) and 10 normal salivary gland tissues (NSGT).   Immunohistochemical (IHC) staining was carried out by the Labeled Strept-Avidin Biotin complex method (LSAB).
 Results: IMP3 expression was detected in NSGT as well as benign and malignant SGTs with different intensities.  The Lowest expression levels were detected in NSGT, while the highest ones were detected in Malignant SGTs.
Conclusion: IMP3 could be used as a diagnostic marker in SGTs.

Keywords

Main Subjects

References

  1. Freling N, Crippa F, Maroldi R. Staging and follow-up of high-grade malignant salivary gland tumours: The role of traditional versus functional imaging approaches – A review. Oral Oncol.2016; 60:157–66.
  2. Sood S, McGurk M, Vaz F. Managment of Salivary Gland Tumors: United Kingdom National Multidisciplinary Guidelines. J Laryngol Otol.2016; 130:S142-S9.
  3. Lima SS, Soares AF, Batista de Amorim RF, Freitas RA. Epidemiologic profile of salivary gland neoplasms. Braz J Otorhinolaryngol.2005; 71:335-40.
  4. To VSH, Chan JYW, Tsang RKY, Wei WI. Review of Salivary Gland Neoplasms. ISRN Otolaryngol.2012; 2012:1-6.
  5. Namboodiripad PCA. A review: Immunological markers for malignant salivary gland tumors. JOBCR.2014; 4:127-34.
  6. Del Gobbo A, Vaira V, Ferrari L, Patriarca C, Di Cristofori A, Ricca D, et al. The Oncofetal Protein IMP3: A Novel Grading Tool and Predictor of Poor Clincal Outcome in Human Gliomas.BMRI.2015; 2015:1-10.
  7. Gong Y, Woda B, Jiang Z. Oncofetal Protein IMP3, a new cancer biomarker. Adv Anat Pathol.2014; 21:191- 200.
  8. Lin C-Y, Chen S-T, Jeng Y-M, Yeh C-C, Chou H-Y, Deng Y-T, et al. Insulin-like growth factor II mRNAbinding protein 3 expression promotes tumor formation and invasion and predicts poor prognosis in oral squamous cell carcinoma. J Oral Pathol Med.2011; 40:699-705.
  9. Mueller-Pillasch F, Pohl B, Wilda M, Lacher U, Beil M, Wallrapp C, et al. Expression of the highly conserved RNA binding protein KOC in embryogenesis. Mech Dev.
  10. Xu H. IMP3: a diagnostic and prognostic biomarker in malignant melanoma. Expert Rev Mol Diagn.2008; 8:557-8.
  11. Jennifer J, Findeis-Hosey, Haodong X. The use of insulin-like growth factor II messenger RNA binding protein-3 in diagnostic pathology. Hum Pathol.2011; 42:303-14.
  12. Ikenberg K, Fritzsche FR, Zuerrer-Haerdi U, Hofmann I, Hermanns T, Seifert H, et al. Insulin-like growth factor II mRNA binding protein 3 (IMP3) is overexpressed in prostate cancer and correlates with higher Gleason scores. BMC Cancer.2010; 10:341.
  13. Kulacoglu S, Erkilinc G. IMP3 Expression in Benign and Malignant Thyroid Tumors and Hyperplastic Nodules. Balcan Med J.2015; 32:30-7.
  14. Findeis-Hosey JJ, Xu H. Insulin-like growth factor IImessenger RNA-binding protein-3 and lung cancer. Biotech Histochem.2011; 87:24-9.
  15. Yan J, Wei Q, Jian W, Qiu B, Wen J, Liu J, et al. IMP3 Predicts Invasion and Prognosis in Human Lung Adenocarcinoma.Lung.2016;194:137-46.
  16. Feng W, Zhou Z, Peters JH, Khoury T, Zhai Q, Q.W, et al. Expression of Insulin like growth factor II mRNA binding protein 3 in esophageal adenocarcinoma and its precursor lesions. Arch Pathol Lab Med.2011; 135:1024-
  17. Lochhead P, Imamura Y, Morikawa T, Kuchiba A, Yamauchi M, Liao Y, et al. Insulin-like growth factor 2 messenger RNA binding protein 3 (IGF2BP3) is a marker of unfavourable prognosis in colorectal cancer. Eur J Cancer.2012; 48:3405-13.
  18. Chen Y-L, Jeng Y-M, Hsu H-C, Lai H-S, Lee P-H, Lai P-L, et al. Expression of insulin-like growth factor II mRNA-binding protein 3 predicts early recurrence and poor prognosis in intrahepatic cholangiocarcinoma. Int J Surg. 2013; 11:85-91.
  19. Wei Q, Yan J, Fu B, Liu J, Zhong L, Yang Q, et al. IMP3 expression is associated with poor survival in cervical squamous cell carcinoma. Hum Pathol.2014; 45:2218-24.
  20. Hsu KF, Shen MR, Huang YF, Cheng YM, Lin SH, Chow NH, et al. Overexpression of the RNA-binding proteins Lin 28B and IGF2BP3 (IMP3) is associated with chemoresistance and poor disease outcome in ovarian cancer. Br J Cancer.2015; 113:414-24.
  21. Xie C, Li Y, Li Q, Chen Y, Yao J, Yin G, et al. Increased insulin mRNA binding protein-3 expression correlates with vascular enhancement of renal cell carcinoma by intravenous contrast-CT and is associated with bone metastases. J Bone Oncol.2015; 4:69-76.
  22. Zhao B, ZhaoY, Jiang HP, Cao YW, Wang YH, Yang XC, et al. The role of insulin-like growth factor axis in bladder cancer: a systemic review and meta analysis. Int J Clin Exp Med. 2016; 9:784-93.
  23. Ismerim AB, Ferreira SV, Lessa AM, Pereira Ju´nior AS, Gurgel CA, Coutinho-Camillo CM, et al. Insulinlike Growth Factor II Messsenger RNA-binding Protein 3 in Salivary Gland Tumors. Appl Immunohistochem Mol Morphol.2016; 24:422-6.
  24. ElShafey MR, Ahmed RA, Mourad MI, Gaballah ET. The oncofetal protein is an indicator of early recurrence and poor outcome in mucoepidermoid carcinoma of salivary glands. Cancer Biol Med. 2016; 13:286-95.
  25. Syrbu SL, Cohen MB. An enhanced Antigen-Retrieval Protocol for Immunohistochemical Staining of Formalin-Fixed, Paraffin-Embedded Tissues. Methods Mol Biol.2011; 717:101-10.
  26. da Silva LP, Serpa MS, Viveiros SK, Sena DAC, de Carvalho Pinho RF, de Abreu Guimaraes LD , et al. Salivary gland tumors in a Brazilian population: A 20- year retrospective and multicentric study of 2292 cases. J Craniomaxillofac Surg.2018; 46:2227-33.
  27. Degrauwe N, Suva ML, Janiszewska M, Riggi N, Stamenkovic I. IMPs: an RNA-binding protein family that provides a link between stem cell maintenance in normal development and cancer. Genes Dev.2016; 30:2459-74.
  28. Afroza K, Gulshan A, Rahman MA. Pattern of distribution of different salivary gland tumor;a retrospective study in NICRH, Dhaka. Bangladesh J Med Sci. 2016; 15:95-8.
  29. Aquino G, Collina F, Sabatino R, Cerrone M, Longo F, Ionna F, et al. Sex Hormone Receptors in Benign and Malignant Salivary Gland Tumors: Prognostic and Predictive Role. Int J Mol Sci. 2018; 19:399.
  30. Phattarataratip E, Kositkittiwanit N, Kajornkiatkul P, Yeunyong P, Ratanapitak R. P120 catenin expression and its correlation with E-cadherin in salivary gland neoplasms. J Oral Biol Craniofac Res. 2019; 9:57-62.
  31. Khattak MS, Ahmad S, Noman N. The histological pattern of salivary gland tumors. Gomal J Med Sci. 2016; 14:203-7.
  32. Sharma S, Bargotra R, Kaul KK. Morphological patterns of salivary gland tumors. JK Science. 2017; 19:48-52.
  33. Sando Z, Fogha JV, Mebada AO, Djomou F, Ndjolo A, Essame JL. Epidemiological and histopathological patterns of salivary gland tumors in Cameroon. Pan Afr Med J. 2016; 23.
  34. Hussain S, Nassem N, Nagi AH. Age, gender and site distribution of salivary gland tumors reported at tertiary care hospitals. Biomedica. 2016; 32.
  35. Wei Q, Zhou H, Zhong L, Shi L, Liu J, Yang Q, et al. IMP3 expression in biopsy specimens as a diagnostic biomarker for colorectal cancer. Hum Pathol.2017; 64:137-44.
  36. Senoo J, Mikata R, Kishimoto T, Hayashi M, Kusakabe Y, Yasui S, et al. Immunohistochemical analysis of IMP3 and p53 expression in endoscopic ultrasoundguided fine needle aspiration and resected specimens of pancreatic diseases. Pancreatology. 2018; 18:176-83.
  37. Kanzaki A, Kudo M, Ansai S-I, Peng W-X, Ishino K, Yamamoto T, et al. Insulin like growth factor II mRNA binding protein as a marker for distinguishing between cutaneous squamous cell carcinoma and keratoacanthoma. Int J Oncol.2016;48:1007-15
  38. Slosar M, Vohra P, Prasad M, Fischer A, Quinlan R, Khan A. IMP3 is differentially expressed in benign and malignant follicular patterned thyroid tumors. Endocr Pathol.2009; 20:149-57.
  39. Bell JL, Wachter K, Muhleck B, Pazaitis N, Kohn M, Lederer M, et al. Insulin-like growth factor 2 mRNAbinding proteins (IGF2BPs): Post-transcriptional drivers of cancer progression? Cell Mol Life Sci. 2013; 70:2657–75.
  40. King RL, Pasha T, Roullet MR, Zhang PJ, Bagg A. IMP-3 is differentially expressed in normal and neoplastic lymphoid. Hum Pathol.2009; 40:1699-705.

Files

Share

How to cite

Statistics